Imunon, INC Form 4 insider transactions

Michael Tardugno, Executive Chairman of Imunon, Inc., reports the acquisition of stock options.

Christine Pellizzari, a director of Imunon, Inc., acquired stock options exercisable for 3,750 shares of common stock at a price of $0.8651 on March 14, 2025.

Imunon's President and CEO, Stacy Lindborg, reports the acquisition of 75,000 stock options exercisable at $0.8651, vesting over two years.

Chief Medical Officer Douglas Vincent Faller receives stock options from Imunon, Inc.

Director Donald P. Braun purchased 25,000 shares of Imunon, Inc. (IMNN) common stock on August 20, 2024, at a price of $1.1792 per share.

Michael Tardugno, Executive Chairman of Imunon, Inc., was granted stock options to purchase 12,500 shares of common stock on December 18, 2024.

Stacy Lindborg, CEO of Imunon, Inc., files an amended Form 4 to report a previously unreported grant of 25,000 restricted stock units (RSUs) received on September 6, 2024.

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., reports the acquisition of stock options.

Director Donald P. Braun reports acquiring options to purchase 9,072 shares of Imunon common stock in lieu of cash board fees.

Christine A. Pellizzari, a director at Imunon, Inc., acquired stock options in lieu of cash for a portion of her board fees.

Director James E. Dentzer acquired 3,634 stock options of Imunon, Inc. in lieu of cash for a portion of board fees.

Director Frederick J. Fritz acquired stock options in Imunon, Inc. in lieu of cash compensation for board fees.

Imunon's President and CEO, Stacy Lindborg, reports the acquisition of stock options in the company.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., was granted stock options in lieu of a cash payment on September 6, 2024.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports the acquisition of stock options in lieu of cash payment increases.

Imunon's President and CEO, Stacy Lindborg, recently purchased 25,000 shares of Imunon common stock on the open market, increasing her direct holdings in the company.

Michael Tardugno, Executive Chairman of Imunon, Inc., purchased 25,000 shares of Imunon common stock on the open market on August 15, 2024.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired 100,000 stock options at an exercise price of $1.22 on June 12, 2024.

Imunon's CEO, Stacy Lindborg, was granted stock options to purchase 112,500 shares of common stock at an exercise price of $1.22 on June 12, 2024.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports the acquisition of stock options.

Director Frederick J. Fritz acquired stock options for 3,500 shares of Imunon, Inc. at an exercise price of $1.22 on June 12, 2024.

Christine A. Pellizzari, a director of Imunon, Inc., acquired stock options on June 12, 2024.

Director James E. Dentzer acquired stock options in Imunon, Inc. on June 12, 2024.

Director Donald P. Braun acquired options to purchase 3,500 shares of Imunon, Inc. common stock at an exercise price of $1.22 on June 12, 2024.

Imunon's CEO, Stacy Lindborg, reported the acquisition of stock options exercisable for 112,500 shares of common stock.

Jeffrey Wayne Church, CFO of Imunon, Inc., reports the acquisition of stock options.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports acquisition of stock options.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired stock options exercisable for 12,500 shares of common stock on March 15, 2024.

Director Frederick J. Fritz acquired stock options for 3,500 shares of Imunon, Inc. at an exercise price of $0.86 on March 15, 2024.

Donald P. Braun, a director of Imunon, Inc., acquired options to purchase 3,500 shares of Imunon common stock at an exercise price of $0.86 on March 15, 2024.